The descriptor 'interstitial lung disease' covers a wide range of clinical conditions, sharing common clinical, radiological and pulmonary function features, and yet having disparate outcomes. They usually present with shortness of breath on exertion and/or cough. Some interstitial lung diseases present with features suggesting a specific diagnosis, whereas others may be difficult to differentiate from each other. The importance of confirming a diagnosis cannot be overemphasised. In certain conditions, for example respiratory bronchiolitis interstitial lung disease or early stage hypersensitivity pneumonitis, simple measures such as smoking cessation or removal from the provoking extrinsic agent may reverse or slow the pathologic process. In others, such as idiopathic pulmonary fibrosis (IPF)/non-specific interstitial pneumonia (NSIP), debate continues about how to best distinguish these entities and which pharmacological agent, if any, should be used in management. No treatments have been found to consistently alter the course of these diseases and treatment guidelines recommend enrolment of patients in high quality clinical trials of therapy where feasible 1 in order that newer therapeutic options may be trialled appropriately and either rejected or accepted into clinical practice, depending upon outcomes.
This review series examines current issues in the assessment and management of some of the most commonly encountered interstitial lung diseases. The evolution in our understanding of the differences between IPF and NSIP and why it is important to differentiate between these conditions in a prognostic sense will be discussed by Glaspole and Goh. Whilst treatment options are limited in both, a diagnosis of NSIP is associated with a less aggressive disease course and in addition, up to 25% of such patients will subsequently develop a connective tissue disease. Specific issues relating to interstitial lung disease associated with connective-tissue disorders where the pace of any associated interstitial lung disease can vary significantly and may or may not warrant treatment will be discussed by Renzoni. Although establishing a diagnosis of pulmonary hypertension (PAH) in interstitial lung disease would seem important for prognostic reasons, as this group has an increased mortality and greater functional impairment, the appropriate treatments for PAH in this setting as opposed to the idiopathic setting, have not been determined and will be discussed by Keating and Williams. A subsequent review by De Boer and Wilsher will update our current understanding and management options in one of the common interstitial lung diseases, sarcoidosis.
Current treatment guidelines regarding diagnosis of idiopathic pulmonary fibrosis (IPF) and related conditions suggest involvement of a 'multidisciplinary team' of clinicians, radiologists and pathologists, where possible, in order to maximize the likelihood of a correct diagnosis as well as maximizing treatment options for patients, including enrolment in formal treatment trials where feasible. 1 Many clinicians do not have access to such teams or trials, but want to maximize outcomes for their patients. Given the lack of proven therapies for IPF, it is encouraging that recent studies have confirmed the benefits of pulmonary rehabilitation (known for sometime in chronic obstructive pulmonary disease) on both exercise capacity and quality of life in interstitial Department of Respiratory and Sleep Medicine, Austin Hospital, Heidelberg, Victoria, Australia lung disease. [2] [3] [4] The first paper in this series, by Holland, 5 discusses the mechanisms underlying the exercise limitation and exercise-induced dyspnoea, which are frequent presenting features of interstitial lung disease and describes the use of exercise training as an effective management tool in this group of conditions where treatment strategies are, too often, limited.
